Hers Review
Women-focused sister brand to Hims spanning GLP-1, hair, skincare, and menopause care.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Quick Verdict
Women-focused sister brand to Hims spanning GLP-1, hair, skincare, and menopause care.
Who it's for: Hers is best suited to women who want a recognizable, publicly traded telehealth platform with broad category coverage, from GLP-1 to hair regrowth to menopause care. in a single account.
Bottom line: A high-volume operator with one of the widest women's-health formularies in telehealth. Specialist clinics may go deeper in any one category, but few rivals match the breadth. The Hims & Hers parent company's scale means broad formulary access and reliable fulfillment, but the high-volume model can mean less personalized provider interactions than smaller specialist clinics.
Compare Hers on price, review history, and fit
Hers may be a strong fit. Before enrolling, compare its published details with three reviewed alternatives. Some links are compensated; editorial scores are independent.
| Provider | Published price | Trustpilot |
|---|---|---|
| Inner Balance | From $150 – $399/mo | 2.7/5 (19) |
| Hone Health | From $25 – $399/mo · not confirmed month-to-month | 4.8/5 (12,311) |
| Gala Health | From $149 – $399/mo | 4.6/5 (3,986) |
- Wide women's formulary in one account
- Both compounded and brand-name GLP-1 access
- Public-company financial transparency
- Pricing tiers can be confusing
- Mixed customer-service reports
- Subscription auto-renewal model
Pros & Cons In Detail
Compare Before You Choose
Compare Hers on price, review history, and program fit.
A positive review is still a reason to compare before enrolling. Some links are compensated; editorial scores are independent.
| Provider | Published price | Trustpilot |
|---|---|---|
| Inner Balance | From $150 – $399/mo | 2.7/5 (19) |
| Hone Health | From $25 – $399/mo · not confirmed month-to-month | 4.8/5 (12,311) |
| Gala Health | From $149 – $399/mo | 4.6/5 (3,986) |
Hers Pricing
Telehealth ads often advertise a low headline price that's the clinic's program fee, not the medication. Here's how the two line items break down at Hers.
| Program / Membership Fee | From $39 first month; $149/mo renewal |
| Medication Cost (From) | From $149 – $449/mo |
For the weight-loss program, Hers' public FAQ lists a $39 first membership month followed by $149/month automatic renewal. Medication is billed separately and an active membership is required, so add the membership price to the specific prescribed treatment before comparing total cost.
Who Hers Is For
Hers is best suited to women who want a recognizable, publicly traded telehealth platform with broad category coverage, from GLP-1 to hair regrowth to menopause care. in a single account.
Women who want one publicly traded telehealth brand for weight loss, hair, skincare, sexual wellness, and menopause under a single account.
Signature Programs
- ›Compounded and brand-name GLP-1 weight loss
- ›Hair regrowth with topical and oral options
- ›Menopause and sexual wellness care
Medication Formulary
The Bottom Line
A high-volume operator with one of the widest women's-health formularies in telehealth. Specialist clinics may go deeper in any one category, but few rivals match the breadth. The Hims & Hers parent company's scale means broad formulary access and reliable fulfillment, but the high-volume model can mean less personalized provider interactions than smaller specialist clinics.
With an editor score of 4.4 / 5 across cost, experience, and trust, Hers is one of the strong mid-tier options in the women's health & hrt category we cover.
See how Hers compares in our full women's health & hrt rankings, or read the Best Telehealth GLP-1 Providers guide. Our methodology explains how we score each provider.
Frequently Asked Questions
- Wilding et al., NEJM 2021 (STEP 1) · Semaglutide 2.4 mg produced 14.9% mean weight loss vs 2.4% placebo at 68 weeks in the STEP 1 trial.
- FDA Federal Register 2024 (Semaglutide shortage end) · FDA removed semaglutide from the drug shortage list in October 2024, ending the legal basis for compounding.
- Jastreboff et al., NEJM 2022 (SURMOUNT-1) · Tirzepatide 15 mg produced 20.9% mean weight loss vs 3.1% placebo at 72 weeks in SURMOUNT-1.
- FDA Federal Register 2024 (Tirzepatide shortage end) · FDA removed tirzepatide from the drug shortage list in October 2024.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.
Alternatives To Hers
Hers does not currently offer a direct online intake. The providers below offer similar programs and are accepting new patients.
Also Competes With
Hers also operates in GLP-1 Weight Loss, Hair Loss, Skincare. Here are other providers in those spaces: